Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors

References

• Semenza GL. Intratumoral Hypoxia and mechanisms of immune evasion mediated by Hypoxia-inducible factors. Physiology (Bethesda). 2021;36(2):73–83.
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26(10):1519–1530.
   PubMed Web of Science ®Google Scholar
• Pugh CW, Ratcliffe PJ. New horizons in hypoxia signaling pathways. Exp Cell Res. 2017;356:116–121.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083.
   PubMed Web of Science ®Google Scholar
• Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001;19:3660–3668.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Swayampakula M, Dedhar S. Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites. 2018;8:E20.
   PubMed Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Dedhar S. pH regulators of the tumor microenvironment. A general overview. In: Supuran CT, Carradori S, editors. pH-interfering agents as chemosensitizers in cancer therapy. London (UK): Elsevier; 2021. p. 13–33.
   Google Scholar
• Benej M, Svastova E, Banova R, et al. CA IX stabilizes intracellular pH to maintain metabolic reprogramming and proliferation in hypoxia. Front Oncol. 2020;10:1462.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27(12):963–970.
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020 14; 10(10): E412.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites. 2017;7(3):48.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol. 2020;12:603–617.
   PubMedGoogle Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci (Lond). 2021;135(10):1233–1249.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Angeli A, Carta F, et al. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36(1):561–580.
   PubMed Web of Science ®Google Scholar
• Chafe SC, Vizeacoumar FS, Venkateswaran G, et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv. 2021;7(35):eabj0364.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Combs J, Singh S, et al. Inhibition of carbonic anhydrase using SLC-149: support for a noncatalytic function of CAIX in breast cancer. J Med Chem. 2021;64(3):1713–1724.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Benzolamide is not a membrane-impermeant carbonic anhydrase inhibitor. J Enzyme Inhib Med Chem. 2004;19:269–273.
   PubMed Web of Science ®Google Scholar
• Supuran CT. An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol. 2020;16(4):297–307.
   PubMed Web of Science ®Google Scholar
• Garbati P, Barbieri R, Calderoni M, et al. Efficacy of a three drug-based therapy for neuroblastoma in mice. Int J Mol Sci. 2021;22(13):6753.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54:1896–1902.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71:3364–3376.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb). 2010;46:8371–8373.
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32:5210–5219.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Mahon BP, Lamas N, et al. Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides. Eur J Med Chem. 2017;132:184–191.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chafe SC, Brown WS, et al. Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology. 2019;157(3):823–837.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Andreucci E, Ruzzolini J, et al. The carbonic anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells. J Enzyme Inhib Med Chem. 2020;35(1):1185–1193.
   PubMed Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Saberi S, et al. Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res. 2019;7(7):1064–1078.
   PubMed Web of Science ®Google Scholar
• Gros SJ, Holland-Cunz SG, Supuran CT, et al. Personalized treatment response assessment for rare childhood tumors using microcalorimetry-exemplified by use of carbonic anhydrase IX and aquaporin 1 inhibitors. Int J Mol Sci. 2019;20(20):4984.
   Web of Science ®Google Scholar
• Genah S, Angeli A, Supuran CT, et al. Effect of carbonic anhydrase IX inhibitors on human endothelial cell survival. Pharmacol Res. 2020;159:104964.
   PubMed Web of Science ®Google Scholar
• Riemann A, Güttler A, Haupt V, et al. Inhibition of carbonic Anhydrase IX by Ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate Daunorubicin or Cisplatin cytotoxicity. Oncol Res. 2018;26(2):191–200.
   PubMed Web of Science ®Google Scholar
• Bernardino RL, Dias TR, Moreira BP, et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells. FEBS J. 2019;286(7):1393–1406.
   PubMed Web of Science ®Google Scholar
• Petrenko M, Güttler A, Funtan A, et al. Combined 3-O-acetylbetulin treatment and carbonic Anhydrase IX inhibition results in additive effects on human breast cancer cells. Chem Biol Interact. 2021;333:109326.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol. 2020;43(7):484–490.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang L, Chew SH, et al. Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia. Redox Biol. 2019;26:101297.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang L, Toyokuni S. Role of carbonic anhydrases in ferroptosis-resistance. Arch Biochem Biophys. 2020;689:108440.
   PubMed Web of Science ®Google Scholar
• Lee SH, Griffiths JR. How and why are cancers acidic? Carbonic anhydrase IX and the homeostatic control of tumour extracellular pH. Cancers (Basel). 2020;12(6):1616.
   PubMed Web of Science ®Google Scholar
• Morgan PE, Pastoreková S, Stuart-Tilley AK, et al. Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am J Physiol Cell Physiol. 2007;293(2):C738–48.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ai L, Mboge MY, et al. UFH-001 cells: a novel triple negative, CAIX-positive, human breast cancer model system. Cancer Biol Ther. 2018;19(7):598–608.
   PubMed Web of Science ®Google Scholar
• Hedlund EE, McDonald PC, Nemirovsky O, et al. Harnessing Induced essentiality: targeting carbonic anhydrase IX and angiogenesis reduces lung metastasis of triple negative breast cancer xenografts. Cancers (Basel). 2019;11(7):1002.
   Web of Science ®Google Scholar
• Mboge MY, Chen Z, Khokhar D, et al. A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells. Biochem J. 2019;476(10):1497–1513.
   PubMedGoogle Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55(11):5591–5600.
   PubMed Web of Science ®Google Scholar
• Bryant JL, Gieling RG, Meredith SL, et al. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer. 2018;142(1):191–201.
   PubMed Web of Science ®Google Scholar
• Xu P, Zhang Y, Ge F, et al. Modulation of tumor microenvironment to enhance radiotherapy efficacy in esophageal squamous cell carcinoma by inhibiting carbonic Anhydrase IX. Front Oncol. 2021;11:637252.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX. J Med Chem. 2018;61(14):6328–6338.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Bua S, et al. Synthesis and biological evaluation of novel N, N’-diaryl cyanoguanidines acting as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem. 2018;77:245–251.
   PubMed Web of Science ®Google Scholar
• Lolak N, Akocak S, Bua S, et al. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem. 2018;77:542–547.
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Mahon BP, Carta F, et al. Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111. Bioorg Med Chem. 2016;24:976–981.
   PubMed Web of Science ®Google Scholar
• Angeli A, Tanini D, Peat TS, et al. Discovery of new selenoureido analogues of 4-(4-fluorophenylureido) benzenesulfonamide as carbonic anhydrase inhibitors ACS. Med Chem Lett. 2017;8:963–968.
   Google Scholar
• Eldehna WM, Abo-Ashour MF, Berrino E, et al. SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX. Bioorg Chem. 2019;83:549–558.
   PubMed Web of Science ®Google Scholar
• Congiu C, Onnis V, Deplano A, et al. Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity. Bioorg Med Chem Lett. 2015;25(18):3850–3853.
   PubMed Web of Science ®Google Scholar
• Moi D, Nocentini A, Deplano A, et al. Appliance of the piperidinyl-hydrazidoureido linker to benzenesulfonamide compounds: synthesis, in vitro and in silico evaluation of potent carbonic anhydrase II, IX and XII inhibitors. Bioorg Chem. 2020;98:103728.
   PubMed Web of Science ®Google Scholar
• Abo-Ashour MF, Eldehna WM, Nocentini A, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. Bioorg Chem. 2019;87:794–802.
   PubMed Web of Science ®Google Scholar
• Alkhaldi AAM, Al-Sanea MM, Nocentini A, et al. 3-Methylthiazolo[3,2-a]benzimidazole-Benzenesulfonamide conjugates as novel carbonic Anhydrase inhibitors endowed with anticancer activity: design, synthesis, biological and molecular modeling studies. Eur J Med Chem. 2020;207:112745.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Fares M, Ceruso M, et al. Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII. Eur J Med Chem. 2016;110:259–266.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eur J Med Chem. 2019;162:147–160.
   PubMed Web of Science ®Google Scholar
• Eldeeb AH, Abo-Ashour MF, Angeli A, et al. Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail/dual tail approaches: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies. Eur J Med Chem. 2021;221:113486.
   PubMed Web of Science ®Google Scholar
• Elbadawi MM, Eldehna WM, Nocentini A, et al. Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: synthesis and evaluation of the carbonic anhydrase inhibitory activities. Eur J Med Chem. 2021;218:113360.
   PubMed Web of Science ®Google Scholar
• Shaldam M, Eldehna WM, Nocentini A, et al. Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors. Eur J Med Chem. 2021;216:113283.
   PubMed Web of Science ®Google Scholar
• Iikuni S, Ono M, Watanabe H, et al. Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy. Theranostics. 2018;8(11):2992–3006.
   PubMed Web of Science ®Google Scholar
• Iikuni S, Watanabe H, Shimizu Y, et al. PET imaging and pharmacological therapy targeting carbonic anhydrase-IX high-expressing tumors using US2 platform based on bivalent ureidosulfonamide. PLoS One. 2020;15(12):e0243327.
   PubMed Web of Science ®Google Scholar
• Iikuni S, Okada Y, Shimizu Y, et al. Modulation of the pharmacokinetics of a Radioligand targeting carbonic Anhydrase-IX with Albumin-Binding Moieties. Mol Pharm. 2021;18(3):966–975.
   PubMedGoogle Scholar
• Bua S, Lomelino C, Murray AB, et al. “A sweet combination”: developing Saccharin and Acesulfame K structures for selectively targeting the tumor-associated carbonic Anhydrases IX and XII. J Med Chem. 2020;63(1):321–333.
   PubMed Web of Science ®Google Scholar
• D’Ascenzio M, Secci D, Carradori S, et al. 1,3-dipolar cycloaddition, HPLC enantioseparation, and docking studies of Saccharin/Isoxazole and Saccharin/Isoxazoline derivatives as selective carbonic Anhydrase IX and XII inhibitors. J Med Chem. 2020;63(5):2470–2488.
   PubMed Web of Science ®Google Scholar
• Akocak S, Güzel-Akdemir Ö, Kishore Kumar Sanku R, et al. Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII. Bioorg Chem. 2020;103:104204.
   PubMed Web of Science ®Google Scholar
• Abdelrahman MA, Ibrahim HS, Nocentini A, et al. Novel 3-substituted coumarins as selective human carbonic anhydrase IX and XII inhibitors: synthesis, biological and molecular dynamics analysis. Eur J Med Chem. 2021;209:112897.
   PubMed Web of Science ®Google Scholar
• Dar’in D, Kantin G, Kalinin S, et al. Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide - A new caspase-activating proapoptotic agent. Eur J Med Chem. 2021;222:113589.
   PubMed Web of Science ®Google Scholar
• Güttler A, Eiselt Y, Funtan A, et al. Betulin sulfonamides as carbonic anhydrase inhibitors and anticancer agents in breast cancer cells. Int J Mol Sci. 2021;22(16):8808.
   PubMed Web of Science ®Google Scholar
• Baglini E, Ravichandran R, Berrino E, et al. Tetrahydroquinazole-based secondary sulphonamides as carbonic anhydrase inhibitors: synthesis, biological evaluation against isoforms I, II, IV, and IX, and computational studies. J Enzyme Inhib Med Chem. 2021;36(1):1874–1883.
   PubMed Web of Science ®Google Scholar
• Antal I, Koneracka M, Kubovcikova M, et al. Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles. Colloids Surf B Biointerfaces. 2021;205:111893.
   PubMed Web of Science ®Google Scholar
• Angeli A, Pinteala M, Maier SS, et al. Tellurides bearing benzensulfonamide as carbonic anhydrase inhibitors with potent antitumor activity. Bioorg Med Chem Lett. 2021;45:128147.
   PubMed Web of Science ®Google Scholar
• Kugler M, Nekvinda J, Holub J, et al. Inhibitors of CA IX enzyme based on polyhedral Boron compounds. Chembiochem. 2021;22(18):2741–2761.
   PubMed Web of Science ®Google Scholar
• Oehler S, Catalano M, Scapozza I, et al. Affinity selections of DNA-encoded chemical libraries on carbonic Anhydrase IX-expressing tumor cells reveal a dependence on ligand valence. Chemistry. 2021 Jun 21;27(35):8985–8993.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Dal Corso A, Widmayer F, et al. Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J Am Chem Soc. 2018;140(5):1617–1621.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Ziffels B, Widmayer F, et al. Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic Anhydrase IX in combination with targeted Interleukin-2. Clin Cancer Res. 2018;24(15):3656–3667.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Figueras E, Pethő L, et al. In vivo antitumor activity of a novel acetazolamide-cryptophycin conjugate for the treatment of renal cell carcinomas. ACS Omega. 2018;3(11):14726–14731.
   PubMed Web of Science ®Google Scholar
• Gouyou B, Millul J, Villa A, et al. Sortase-mediated site-specific modification of Interleukin-2 for the generation of a tumor-targeting acetazolamide-cytokine conjugate. ACS Omega. 2020;5(40):26077–26083.
   PubMed Web of Science ®Google Scholar
• Mondal UK, Doroba K, Shabana AM, et al. PEG linker length strongly affects tumor cell killing by PEGylated carbonic anhydrase inhibitors in hypoxic carcinomas expressing carbonic anhydrase IX. Int J Mol Sci. 2021;22(3):1120.
   PubMed Web of Science ®Google Scholar
• Sarnella A, D’Avino G, Hill BS, et al. A novel inhibitor of carbonic anhydrases prevents Hypoxia-induced TNBC cell plasticity. Int J Mol Sci. 2020;21(21):8405.
   Web of Science ®Google Scholar
• Krasavin M, Kalinin S, Sharonova T, et al. Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents. J Enzyme Inhib Med Chem. 2020;35(1):1555–1561.
   PubMed Web of Science ®Google Scholar
• Burianova V, Kalinin S, Supuran CT, et al. Radiotracers for positron emission tomography (PET) targeting tumour-associated carbonic anhydrase isoforms. Eur J Med Chem. 2021;213:113046.
   PubMed Web of Science ®Google Scholar
• Koyuncu I, Tülüce Y, Slahaddin Qadir H, et al. Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells. J Enzyme Inhib Med Chem. 2019;34(1):703–711.
   PubMed Web of Science ®Google Scholar
• Sharma V, Kumar R, Angeli A, et al. Tail approach synthesis of novel benzenesulfonamides incorporating 1,3,4-oxadiazole hybrids as potent inhibitor of carbonic anhydrase I, II, IX, and XII isoenzymes. Eur J Med Chem. 2020;193:112219.
   PubMed Web of Science ®Google Scholar
• Ciccone V, Filippelli A, Angeli A, et al. Pharmacological Inhibition of CA-IX impairs tumor cell proliferation, migration and invasiveness. Int J Mol Sci. 2020;21(8):2983.
   Web of Science ®Google Scholar
• Venkateswaran G, Dedhar S. Interplay of carbonic anhydrase IX with amino acid and acid/base transporters in the hypoxic tumor microenvironment. Front Cell Dev Biol. 2020;8:602668.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Mongre RK, Prakash A, et al. Anti-breast cancer action of carbonic anhydrase IX inhibitor 4-[4-(4-Benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-benzylidene-hydrazinocarbonyl]-benzenesulfonamide (BSM-0004): in vitro and in vivo studies. J Enzyme Inhib Med Chem. 2021;36(1):954–963.
   PubMed Web of Science ®Google Scholar
• Temiz E, Koyuncu I, Durgun M, et al. Inhibition of carbonic anhydrase IX promotes apoptosis through Intracellular pH level alterations in cervical cancer cells. Int J Mol Sci. 2021;22(11):6098.
   PubMed Web of Science ®Google Scholar
• Yamali C, Inci Gul H, Ozli G, et al. Exploring of tumor-associated carbonic anhydrase isoenzyme IX and XII inhibitory effects and cytotoxicities of the novel N-aryl-1-(4-sulfamoylphenyl)-5-(thiophen-2-yl)-1H-pyrazole-3-carboxamides. Bioorg Chem. 2021;115:105194.
   PubMed Web of Science ®Google Scholar
• Elimam DM, Elgazar AA, Bonardi A, et al. Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: design, synthesis and biological evaluation. Eur J Med Chem. 2021;225:113800.
   PubMed Web of Science ®Google Scholar
• Millul J, Krudewig C, Zana A, et al. Immunotherapy with Immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX. Mol Cancer Ther. 2021;20(3):512–522.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem. 2021;36(1):1702–1714.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 2014;53:4231–4235.
   PubMed Web of Science ®Google Scholar
• Marks IS, Gardeen SS, Kurdziel SJ, et al. Development of a small molecule Tubulysin B conjugate for treatment of carbonic anhydrase IX receptor expressing cancers. Mol Pharm. 2018;15:2289–2296.
   PubMedGoogle Scholar
• Buller F, Steiner M, Frey K, et al. Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem Biol. 2011;6:336–344.
   PubMed Web of Science ®Google Scholar
• An R, Lin B, Zhao S, et al. Discovery of novel artemisinin-sulfonamide hybrids as potential carbonic anhydrase IX inhibitors with improved antiproliferative activities. Bioorg Chem. 2020;104:104347.
   PubMed Web of Science ®Google Scholar
• Yu H, Hou Z, Tian Y, et al. Design, synthesis, cytotoxicity and mechanism of novel dihydroartemisinin-coumarin hybrids as potential anti-cancer agents. Eur J Med Chem. 2018 May 10;151:434–449.
   PubMed Web of Science ®Google Scholar
• Tian Y, Liang Z, Xu H, et al. Design, synthesis and cytotoxicity of novel Dihydroartemisinin-Coumarin hybrids via click chemistry. Molecules. 2016;21(6):758.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu Z, Xia S, et al. Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. Eur J Med Chem. 2021;216:113300.
   PubMed Web of Science ®Google Scholar
• Elzahhar PA, Abd El Wahab SM, Elagawany M, et al. Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases. Eur J Med Chem. 2020;200:112439.
   PubMed Web of Science ®Google Scholar
• Berrino E, Angeli A, Zhdanov DD, et al. Azidothymidine “Clicked” into 1,2,3-Triazoles: first report on carbonic Anhydrase-Telomerase dual-hybrid inhibitors. J Med Chem. 2020;63:7392–7409.
   PubMed Web of Science ®Google Scholar
• Teodori E, Braconi L, Bua S, et al. Dual P-Glycoprotein and CA XII inhibitors: a new strategy to reverse the P-gp mediated multidrug resistance (MDR) in cancer cells. Molecules. 2020;25:1748.
   PubMed Web of Science ®Google Scholar
• Krasavin M, Sharonova T, Sharoyko V, et al. Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity. J Enzyme Inhib Med Chem. 2020;35(1):665–671.
   PubMed Web of Science ®Google Scholar
• Ceni C, Catarzi D, Varano F, et al. Discovery of first-in-class multi-target adenosine A2A receptor antagonists-carbonic anhydrase IX and XII inhibitors. 8-Amino-6-aryl-2-phenyl-1,2,4-triazolo [4,3-a]pyrazin-3-one derivatives as new potential antitumor agents. Eur J Med Chem. 2020;201:112478.
   PubMed Web of Science ®Google Scholar
• Lee SY, Namasivayam V, Boshta NM, et al. Discovery of potent nucleotide pyrophosphatase/phosphodiesterase3 (NPP3) inhibitors with ancillary carbonic anhydrase inhibition for cancer (immuno)therapy. RSC Med Chem. 2021;12(7):1187–1206.
   PubMedGoogle Scholar
• Petreni A, Bonardi A, Lomelino C, et al. Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells. Eur J Med Chem. 2020;190:112112.
   PubMed Web of Science ®Google Scholar
• Mujumdar P, Kopecka J, Bua S, et al. Carbonic anhydrase XII inhibitors overcome temozolomide resistance in glioblastoma. J Med Chem. 2019;62(8):4174–4192.
   PubMed Web of Science ®Google Scholar
• Battke C, Kremmer E, Mysliwietz J, et al. Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother. 2011;60(5):649–658.
   PubMed Web of Science ®Google Scholar
• Alterio V, Kellner M, Esposito D, et al. Biochemical and structural insights into carbonic anhydrase XII/Fab6A10 complex. J Mol Biol. 2019;431(24):4910–4921.
   PubMed Web of Science ®Google Scholar
• Gondi G, Mysliwietz J, Hulikova A, et al. Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res. 2013;73(21):6494–6503.
   PubMed Web of Science ®Google Scholar
• Fiedler L, Kellner M, Oos R, et al. Fully automated production and characterization of 64 Cu and proof-of-principle small-animal PET imaging using 64 Cu-labelled CA XII targeting 6A10 Fab. ChemMedChem. 2018;13(12):1230–1237.
   PubMed Web of Science ®Google Scholar
• Fiedler L, Kellner M, Gosewisch A, et al. Evaluation of 177Lu[Lu]-CHX-A″-DTPA-6A10 Fab as a radioimmunotherapy agent targeting carbonic anhydrase XII. Nucl Med Biol. 2018;60:55–62.
   PubMed Web of Science ®Google Scholar
• Von Neubeck B, Gondi G, Riganti C, et al. An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo. Int J Cancer. 2018;143(8):2065–2075.
   PubMed Web of Science ®Google Scholar
• Li G, Chen TW, Nickel AC, et al. Carbonic anhydrase XII is a clinically significant, molecular tumor-subtype specific therapeutic target in glioma with the potential to combat invasion of brain tumor cells. Onco Targets Ther. 2021;14:1707–1718.
   PubMed Web of Science ®Google Scholar
• Zatovicova M, Jelenska L, Hulikova A, et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des. 2010;16(29):3255–3263.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40:2485–2565.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev. 2018;38:1799–1836.
   PubMed Web of Science ®Google Scholar
• Zheng C, Song Q, Zhao H, et al. A nanoplatform to boost multi-phases of cancer-immunity-cycle for enhancing immunotherapy. J Control Release. 2021;339:403–415.
   PubMed Web of Science ®Google Scholar